This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $515,812 to The Johns Hopkins University to study the progression of HPV-related oropharynx cancer (HPV-OPC) and how it differs between individuals with and without HIV. The study aims to: 1) characterize the impact of HIV on oral HPV16 persistence, 2) evaluate the performance of oral and blood biomarkers for...
This $598,940 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) aims to characterize the longitudinal events of oral high-risk human papillomavirus (OHR-HPV) infection among an at-risk population of non-heterosexual males living with or without HIV in Nigeria. The primary objectives are to: 1) determine the association between HIV clinical markers, oral-anogenital contact, and...
This federal Project Grant award of $2,740,126, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate the mechanisms by which HIV infection contributes to the development of oropharyngeal cancer (OPC) in people living with HIV (PWH). The key objectives are to: 1) Determine the HPV types present in OPC from PWH and how T cell-mediated anti-tumor immunity is impaired;...
This $329,737 Project Grant awarded on September 12, 2023 by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), is supporting the development of a rapid, easy-to-use diagnostic platform for the point-of-care detection of high-risk HPV in saliva. The grantee, Innotech Precision Medicine, Inc., is working to create an innovative electrochemical biosensor that combines CRISPR-Cas12 technology with their...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund research to investigate the role of antiretroviral therapy (ART) on susceptibility to oral human papillomavirus (HPV) infection. The $1,913,543 award to Louisiana State University Health Sciences Center New Orleans will support three specific aims: 1) comparing the prevalence and incidence of oral HPV infection...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $451,000.00 to the University of Chicago to conduct research aimed at deciphering the mechanisms behind patient responses to a novel immunotherapy targeting human papillomavirus (HPV) associated head and neck cancer. The key objectives of this 2-year research project are to leverage patient tumor biopsies, plasma samples,...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to the University of Arizona in the amount of $118,763 for the period of September 1, 2024 to August 31, 2026. The grant will support Dr. Robert Jackson's research focused on assessing the role of human papillomavirus type 16 (HPV16) in transforming versus productive infections in oral epithelial tissues. The research aims to characterize the viral...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $642,488 to a collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences. The funding will support a 5-year research project focused on understanding the mechanisms by which human papillomavirus (HPV) promotes immune evasion in head and neck squamous cell carcinomas (HNSCC)....
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $315,000 to The Ohio State University to develop novel antibody therapeutics targeting the human papillomavirus (HPV) oncoproteins E6 and E7. The goal is to leverage the university's unique platform of HPV-specific human monoclonal antibodies to generate dimeric IgA molecules that can efficiently inhibit the growth of...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $315,000 to the University of California, Los Angeles (UCLA) to conduct a longitudinal study on the oral microbiome of HIV-exposed uninfected (HEU), HIV-positive, and HIV-unexposed uninfected children aged 3-4 in Western Kenya. The study will collect and analyze 1,080 oral swab samples over one year to understand how...